Celltrion Launches Tocilizumab Biosimilar Avtozma in Japan, Expanding Autoimmune Portfolio to Four
Lead
Celltrion (068270.KS) began selling Avtozma, a biosimilar of Roche's blockbuster anti-IL-6 antibody Actemra (tocilizumab), in Japan on April 28, 2026, the company confirmed on the same day. The launch — handled directly by the firm's Japanese subsidiary — lifts Celltrion's autoimmune lineup in the country to four products and intensifies pricing competition in a segment historically anchored by branded biologics.
What Happened
According to Chosun Biz, Avtozma cleared Japan's Ministry of Health, Labour and Welfare (MHLW) in September 2025 with label coverage for rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), Castleman disease (CD), and cytokine release syndrome (CRS) — the four core indications carried by Roche's originator. The Korea Times reported that the commercial debut comes after a seven-month post-approval window and that both intravenous and subcutaneous formulations are on the Japanese market from day one.
Celltrion said its Japan unit will distribute Avtozma directly rather than through a partner, and introduced the product to clinicians at the 70th Japan College of Rheumatology Annual Scientific Meeting ahead of launch, per Chosun Biz. The Japan portfolio now spans Remsima (infliximab), Yuflyma (adalimumab), Stekima (ustekinumab) — which Celltrion launched in August 2025 — and Avtozma. Separately, Omlyclo (omalizumab) received MHLW marketing authorization in March 2026 and is queued for a subsequent commercial rollout, Chosun Biz reported.
Sources for this section: Korea Times, Chosun Biz, Celltrion company statement.
Business Impact
Japan is one of the few large biosimilar markets where Celltrion has secured durable double-digit volume share without relying on an external partner. Per Celltrion's own disclosure cited by Chosun Biz, Remsima holds 44% and Yuflyma 19% of their respective Japanese reference-drug segments — share levels that frame Avtozma's entry not as a speculative bet but as a fourth product layered onto an established direct-sales channel. The originator, Roche's Actemra, is a multi-indication anchor in Japanese rheumatology; even modest share capture by a biosimilar with both IV and SC presentations translates into meaningful pull-through given that subcutaneous tocilizumab is the higher-volume format in chronic RA maintenance.
The strategic read for institutional investors is portfolio compounding: each additional autoimmune SKU sold through the same Japanese sales force lowers the marginal selling cost of the next launch. With Stekima (August 2025), Avtozma (April 2026), and Omlyclo (approved March 2026) layered within roughly eight months, Celltrion is converting Japan from a two-product market — Remsima plus Yuflyma — into a four-to-five-product franchise inside one fiscal cycle.
Industry & Historical Context
Tocilizumab biosimilars are a globally contested category. Avtozma is Celltrion's response to entrants from Biogen and Fresenius Kabi that have already secured EU and U.S. clearances for tocilizumab biosimilars, and Japan is strategically attractive because MHLW reimbursement frameworks have generally accelerated biosimilar uptake faster than the U.S. Medicare environment. Celltrion's own Japan track record is the most relevant precedent: Remsima, the first infliximab biosimilar to launch in Japan over a decade ago, climbed to its current 44% segment share through direct-sales execution — a playbook the company is now reapplying to tocilizumab with both IV and SC versions available simultaneously, narrowing the format gap that often slows biosimilar penetration in chronic-care settings.
[Chart: see article cover image]
What to Watch
Three concrete monitoring points over the next two quarters: (1) Celltrion's Q2 and Q3 2026 earnings disclosures via Korea's DART (Data Analysis, Retrieval and Transfer System) for the first segmented contribution from Avtozma and Stekima in Japan; (2) MHLW's NHI drug-price listing updates, which determine reimbursed price points for tocilizumab biosimilars; and (3) the commercial launch date for Omlyclo following its March 2026 approval, which will mark Celltrion's fifth Japanese autoimmune/allergy product and complete the post-Remsima portfolio expansion phase.
Sources: - Korea Times — https://www.koreatimes.co.kr/business/20260428/celltrion-enters-japanese-market-for-arthritis-treatments-with-new-biosimilar?utm_source=rss - Chosun Biz — https://biz.chosun.com/science-chosun/bio/2026/04/28/T5NYGANTYZDBBGEW3B22G64UYU/ - Celltrion corporate site — https://www.celltrion.com
By LineVest Markets Desk — 2026-04-28 This article is for informational purposes only and does not constitute investment advice.
[Chart: see article cover image]
